autologous platelet-rich plasma (04c6f6)

Autologous platelet-rich plasma is an individualized **autologous regenerative biologic therapy** prepared from a patient's own whole blood by centrifugation to concentrate platelets and associated growth factors and cytokines. In the referenced Phase 3 prospective, single-arm, open-label study led by Stylianos Kapetanakis, it is administered as **intradiscal and intra-articular injection** for early-stage lumbar degenerative disc disease and facet joint syndrome. The therapeutic rationale is that concentrated platelet-derived bioactive mediators may support tissue repair, extracellular matrix synthesis, modulation of local inflammation, and immunoregulatory effects within degenerative lumbar discs and facet joints. This is not a branded pharmaceutical product but a patient-specific autologous biologic preparation.

Other names

autologous PRPautologous platelet-rich-plasmaplatelet-rich plasma